Caribou Biosciences (CRBU) Competitors $2.82 +0.19 (+7.22%) Closing price 04:00 PM EasternExtended Trading$2.87 +0.05 (+1.77%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. OCS, ORKA, BGM, MNMD, VALN, PROK, ANAB, KURA, AVBP, and PHATShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Oculis (OCS), Oruka Therapeutics (ORKA), BGM Group (BGM), Mind Medicine (MindMed) (MNMD), Valneva (VALN), ProKidney (PROK), AnaptysBio (ANAB), Kura Oncology (KURA), ArriVent BioPharma (AVBP), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Its Competitors Oculis Oruka Therapeutics BGM Group Mind Medicine (MindMed) Valneva ProKidney AnaptysBio Kura Oncology ArriVent BioPharma Phathom Pharmaceuticals Caribou Biosciences (NASDAQ:CRBU) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Does the media favor CRBU or OCS? In the previous week, Oculis had 5 more articles in the media than Caribou Biosciences. MarketBeat recorded 7 mentions for Oculis and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.17 beat Oculis' score of 0.53 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CRBU or OCS? Caribou Biosciences presently has a consensus price target of $6.67, suggesting a potential upside of 136.41%. Oculis has a consensus price target of $41.00, suggesting a potential upside of 87.90%. Given Caribou Biosciences' higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Oculis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk & volatility, CRBU or OCS? Caribou Biosciences has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CRBU or OCS? 77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings and valuation, CRBU or OCS? Oculis has lower revenue, but higher earnings than Caribou Biosciences. Oculis is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.99M26.29-$149.10M-$1.78-1.58Oculis$780K1,221.36-$97.43M-$2.67-8.17 Is CRBU or OCS more profitable? Caribou Biosciences has a net margin of -1,800.93% compared to Oculis' net margin of -13,958.12%. Caribou Biosciences' return on equity of -62.35% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% Oculis -13,958.12%-90.31%-67.85% SummaryCaribou Biosciences beats Oculis on 10 of the 15 factors compared between the two stocks. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$244.91M$3.48B$6.17B$10.68BDividend YieldN/A2.27%5.70%4.84%P/E RatioN/A23.3929.4727.36Price / Sales26.29485.50589.24132.03Price / CashN/A45.2825.8230.35Price / Book1.0110.6112.526.69Net Income-$149.10M-$52.56M$3.32B$276.59M7 Day Performance18.49%4.94%2.43%0.97%1 Month Performance66.86%16.10%8.78%3.95%1 Year Performance41.00%14.51%62.11%36.40% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.5605 of 5 stars$2.82+7.2%$6.67+136.4%+31.5%$244.91M$9.99M0.00100Gap UpOCSOculis2.4466 of 5 stars$21.00-0.4%$41.00+95.2%+55.0%$920.84M$780K-7.872Short Interest ↑ORKAOruka Therapeutics2.8153 of 5 stars$25.50+4.1%$41.80+63.9%-7.7%$917.17MN/A-9.07N/AAnalyst DowngradeBGMBGM Group0.2863 of 5 stars$9.49+1.7%N/A+19.7%$907.08M$25.10M0.00298Short Interest ↑Gap UpMNMDMind Medicine (MindMed)3.4026 of 5 stars$12.25+3.7%$27.83+127.2%+106.5%$898.60MN/A-8.0140Gap UpVALNValneva2.9617 of 5 stars$10.50+1.3%$15.00+42.9%+70.7%$891.07M$183.52M-10.71700Short Interest ↓PROKProKidney2.5672 of 5 stars$2.99-1.0%$6.25+109.0%+50.8%$888.73M$80K-5.253News CoverageANABAnaptysBio2.7275 of 5 stars$32.46+3.5%$52.00+60.2%-1.0%$878.27M$91.28M-7.25100Analyst RevisionKURAKura Oncology4.2841 of 5 stars$9.93+0.8%$24.67+148.4%-45.3%$854.95M$53.88M-4.39130News CoverageAnalyst ForecastAVBPArriVent BioPharma1.4862 of 5 stars$20.90+0.2%$39.14+87.3%-33.1%$846.27MN/A-5.2040PHATPhathom Pharmaceuticals3.1038 of 5 stars$12.53+6.0%$17.50+39.7%-19.4%$838.55M$55.25M-2.65110News CoverageAnalyst Upgrade Related Companies and Tools Related Companies Oculis Competitors Oruka Therapeutics Competitors BGM Group Competitors Mind Medicine (MindMed) Competitors Valneva Competitors ProKidney Competitors AnaptysBio Competitors Kura Oncology Competitors ArriVent BioPharma Competitors Phathom Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
